Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Camellia Sinensis leaf extract contributes to increasing energy expenditure and calorie consumption by increasing thermogenesis. The purpose of this study is to evaluate the efficacy of Camellia Sinensis on basal metabolism and body composition in overweight women or with obesity in postmenopause.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dietary supplement | Active Comparator | Extract from Camellia Sinensis leaf |
|
| Placebo | Placebo Comparator | Tablets of the same size as the active component |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Camellia Sinensis leaf extract | Dietary Supplement | 2 tablets per day of 150 mg (1 before lunch and 1 before dinner) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes on energy expenditure | Basal metabolic rate (Kcal/day) | Changes from baseline energy expenditure at 4 and at 8 weeks |
| Changes on energy expenditure | 24 h urinary nitrogen (g/24 h) | Changes from baseline energy expenditure at 4 and at 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Changes on body composition | Fat Free Mass (g), Fat Mass (g), Visceral Adipose Tissue (g) | Changes from baseline body composition at 4 and at 8 weeks |
| Changes on anthropometry | Weight (kg) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mariangela Rondanelli | Recruiting | Pavia | 27100 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Combination Product | 2 tablets per day of 150 mg (1 before lunch and 1 before dinner) |
|
| Changes from baseline anthropometry at 4 and at 8 weeks |
| Changes on anthropometry | Body Mass Index (kg/m2) | Changes from baseline anthropometry at 4 and at 8 weeks |
| Changes on anthropometry | Waist circumference (cm) | Changes from baseline anthropometry at 4 and at 8 weeks |
| Changes on insulin resistance | Homeostasis Model Assessment (pt) for evaluate insulin resistance if > 2,4 | Changes from baseline insulin resistance at 4 and at 8 weeks |
| Changes on carbohydrate profile | Glycemia (mg/dl) | Changes from baseline carbohydrate profile at 4 and at 8 weeks |
| Changes on carbohydrate profile | Insulin (mcIU/ml) | Changes from baseline carbohydrate profile at 4 and at 8 weeks |
| Changes on lipid profile | Total Cholesterol (mg/dl), High Density Lipoprotein Cholesterol (mg/dl), Low Density Lipoprotein Cholesterol (mg/dl), Tryglicerides (mg/dl) | Changes from baseline lipid profile at 8 weeks |
| Changes on inflammation | C-Reactive Protein (mg/dl) | Changes from baseline inflammation at 8 weeks |
| Changes on incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Alanine Aminotrasferase (IU/l), Aspartate Aminotrasferase (IU/I) | Changes from baseline incidence of Treatment-Emergent Adverse Events at 8 weeks |
| Changes on incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Gamma Glutamyl Trasferase (U/l) | Changes from baseline incidence of Treatment-Emergent Adverse Events at 8 weeks |
| Changes on citokine profile | Adiponectin (microg/ml) | Changes from baseline citokine profile at 4 and at 8 weeks |
| Changes on citokine profile | Leptin (ng/ml) | Changes from baseline citokine profile at 4 and at 8 weeks |
| Changes on plasma catecholamine profile | Adrenalin (ng/ml), Noradrenalin (ng/ml) | Changes from baseline plasma catecholamine profile at 4 and at 8 weeks |
| Changes on satiety | Haber test (pt) for evaluation of satiety from 0 (no satiety) to 10 (a lot of satiety) | Changes of satiety through 8 weeks |